Abstract: One embodiment provides a method of sound source enumeration and direction of arrival (DoA) estimation. The method, the method includes estimating, by an enumeration module, a number of sound sources associated with an acoustic signal. The estimating includes selecting a specific parametric model from a generalized model. The generalized model is related to a microphone array architecture used to capture the acoustic signal. The method further includes estimating, by a DoA module, a direction of arrival of each sound source of the number of sound sources based, at least in part, on the selected model. The estimating the number of sound sources and estimating the DoA of each sound source are performed using a Bayesian framework.

Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing a water-soluble active pharmaceutical ingredient are disclosed. The functional coating provides for immediate release or controlled release of the active pharmaceutical ingredient. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Abstract: The disclosure relates to the technical field of electrochemical energy storage material preparation, and discloses an asphalt-based hollow activated carbon microsphere and a preparation method thereof, an electrode sheet, and a supercapacitor. The preparation method of the asphalt-based hollow activated carbon microsphere comprises the following steps of: (1) mixing an asphalt of low ash content with a solvent to obtain a mixed asphalt solution; (2) subjecting the mixed asphalt solution to spray pyrolysis in an inert atmosphere to obtain a hollow carbon microsphere; (3) mixing the hollow carbon microsphere with an activating agent, and activating to obtain activated carbon; (4) subjecting the activated carbon to acid pickling and water washing to remove impurities, and drying to obtain the hollow activated carbon microsphere. The method has the features of simple process steps, low preparation cost, being suitable for continuous production and the like.

Abstract: Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain.

Abstract: Nuclear transport modulators are disclosed. The compounds can inhibit nuclear transporters such as the exportin-1 transporter. The compounds and pharmaceutical compositions comprising the compounds can be used to treat neurological diseases and cancer.

Abstract: Excipient granulations containing a viscosifying agent, a disintegrant, and one or more additional excipients are disclosed. An excipient granulation can be combined with a pharmaceutical granulation to provide a pharmaceutical composition. The excipient granulations can be used to increase the viscosity of an aqueous composition such as an oral pharmaceutical composition. When added to an aqueous solution, the excipient granulation can dissolve to provide a suspension of the pharmaceutical granules in a viscous solution. The excipient granulation can be used to improve the palatability of oral pharmaceutical compositions containing a pharmaceutical granulation.

Abstract: Pharmaceutical compositions including a pharmaceutical granulation comprising 4-((L-valyl)oxy) butanoic acid and an excipient granulation are disclosed. When the pharmaceutical compositions are combined and mixed with water the excipient granules rapidly dissolve to form a viscous solution with a pharmaceutical granulation suspended in the viscous solution. The pharmaceutical granulations provide palatable oral pharmaceutical compositions.

Abstract: Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain.

Abstract: The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.

Abstract: The present disclosure is directed synthetic methods for the preparation of 4-valyloxybutyric acid. The synthetic methods described herein employ a diverse array of protecting group strategies and reaction conditions. Additionally, the present disclosure is directed to compounds useful as synthetic intermediates in the preparation of 4-valyloxybutyric acid.

Abstract: The present disclosure is directed synthetic methods for the preparation of 4-valyloxybutyric acid. The synthetic methods described herein employ a diverse array of protecting group strategies and reaction conditions. Additionally, the present disclosure is directed to compounds useful as synthetic intermediates in the preparation of 4-valyloxybutyric acid.

Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Abstract: Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and ?-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.

Abstract: Pharmaceutical compositions of 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and ?-hydroxybutyric acid following oral administration of the pharmaceutical compositions to healthy subjects are disclosed.

Abstract: Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and ?-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.

Abstract: Crystalline 4-((L-valyl)oxy)butanoic acid, methods of preparing crystalline 4-((L-valyl)oxy)butanoic acid, pharmaceutical compositions of crystalline 4-((L-valyl)oxy)butanoic acid, and methods of treatment using crystalline 4-((L-valyl)oxy)butanoic acid are disclosed.

Abstract: A method of multi-talker separation using a 3-tuple coprime microphone array, including generating, by a subarray signal processing module, a respective subarray data set for each microphone subarray of the 3-tuple coprime microphone array based, at least in part, on an input acoustic signal comprising at least one speech signal. The input acoustic signal is captured by the 3-tuple coprime microphone array. The 3-tuple coprime microphone array includes three microphone subarrays. The method includes determining, by the subarray signal processing module, a point by point product of the three subarray data sets; and determining, by the subarray signal processing module, a cube root of the point by point product to yield an acoustic signal output data. The acoustic signal output data has an output amplitude and an output phase corresponding to an input amplitude and an input phase of a selected speech signal of the at least one speech signal.

Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Abstract: The present invention relates compounds of Formula (A) as NK-1 receptor antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to NK-1 receptor in humans. More specifically, the compounds and/or pharmaceutical compositions of the present invention are believed to potentially offer therapeutic benefits to patients who suffer, among others, chemotherapy-induced nausea and vomit (CINV) and/or post-operative nausea and vomit (PONV).

Abstract: Pharmaceutical compositions of 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and ?-hydroxybutyric acid following oral administration of the pharmaceutical compositions to healthy subjects are disclosed.